Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases

Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases

Saved in:

Bibliographic Details
Main Authors:	Andrea Angeletti, Sofia Bin, Xhuliana Kajana, Sonia Spinelli, Carolina Bigatti, Gianluca Caridi, Giovanni Candiano, Francesca Lugani, Enrico E. Verrina, Edoardo La Porta, Alberto Magnasco, Maurizio Bruschi, Paolo Cravedi, Gian Marco Ghiggeri
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Kidney International Reports
Subjects:	anti-NEPHRIN antibodies daratumumab focal segmental glomerulosclerosis minimal change disease nephrotic syndrome rituximab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924016267
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Subcutaneous Rituximab in Idiopathic Nephrotic Syndrome
by: Paolo Cravedi, et al.
Published: (2024-11-01)

A Case Series of 4 Patients with Congenital Nephrotic Syndrome
by: Zehra Aydın, et al.
Published: (2023-03-01)

Detection of Antinephrin Antibodies in Childhood Idiopathic Nephrotic Syndrome
by: Gaia Bianchi, et al.
Published: (2025-02-01)

Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis
by: Decimo Silvio Chiarenza, et al.
Published: (2025-01-01)

Nephrotic syndrome caused by recurrent podocytopathy after living donor renal transplantation with elevated anti-nephrin antibody levels: a case report and a review
by: Ryoichi Miyazaki, et al.
Published: (2025-04-01)

Daratumumab
by: Vishnu Gopal, et al.
Published: (2020-01-01)

CASE OF NON-SEVERE CONGENITAL NEPHROTIC SYNDROME
by: I. S. Kostushina, et al.
Published: (2014-11-01)

Protective Effects of <i>Physalis angulata</i> on Podocythopathies Through B-Cell-Activating Factor Inhibition in Doxorubicin-Induced Nephrotic Syndrome Rat Model
by: Astrid K. Kardani, et al.
Published: (2025-03-01)

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience
by: Andrea Angeletti, et al.
Published: (2025-08-01)

WCN25-3004 ANTi-NEPHRIN ANTIBODIES IN A LARGE COHORT OF PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME
by: Andrea Angeletti, et al.
Published: (2025-02-01)

Glomerulosclerosis is a prognostic risk factor in patients with membranous nephropathy and non-nephrotic proteinuria
by: Jing Sun, et al.
Published: (2023-12-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024-07-01)

Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study
by: Mauro Passucci, et al.
Published: (2024-04-01)

Glomerular parietal epithelial expression of CD44 in minimal change nephrotic syndrome and primary focal segmental glomerulosclerosis: A clinico-pathological study
by: Nithin E Paul, et al.
Published: (2023-07-01)

A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome
by: Liu Wu, et al.
Published: (2021-01-01)

The Novel Use of Daratumumab in the Treatment of Refractory Autoimmune Pulmonary Alveolar Proteinosis
by: April Strong, et al.
Published: (2025-06-01)

Assessment of podocyte detachment as a pivotal step in the development of focal segmental glomerulosclerosis
by: Ikbal Ahmed Abdo Elkholy, et al.
Published: (2024-11-01)

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
by: Hua Jiang, et al.
Published: (2024-12-01)

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature
by: Noa Biran, et al.
Published: (2025-03-01)

Proteomic profiling of kidney biopsies in nephrotic syndrome [version 1; peer review: 2 approved, 1 approved with reservations]
by: Emily Williams, et al.
Published: (2024-12-01)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)

Steroid-Resistant Nephrotic Syndrome Is Associated With a Unique Genetic Profile in a Highly Admixed Pediatric Population
by: Andreia Watanabe, et al.
Published: (2024-12-01)

Focal segmental glomerulosclerosis: current status of the problem
by: I. T. Murkamilov, et al.
Published: (2020-01-01)

IgA Nephropathy Associated with IgA Vasculitis Coexisting with Focal Segmental Glomerulosclerosis Tip Variant
by: Zitlali Guadalupe Paulín Zepeda, et al.
Published: (2023-07-01)

Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
by: Sreedhar Jayakrishnan Cherulil, et al.
Published: (2025-01-01)

Rituximab in the treatment of refractory nephrotic syndrome with massive pleural effusion: one case report
by: Zhang Shuo-fan, et al.
Published: (2021-01-01)

Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report
by: Zewei Chen, et al.
Published: (2025-02-01)

Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome
by: Omri Feder, et al.
Published: (2025-03-01)

Research advances of rituximab in the treatment of children with frequent relapse or steroid-dependent nephrotic syndrome
by: Wen-jing Kang, et al.
Published: (2024-10-01)

Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome
by: Jialu Liu, et al.
Published: (2024-05-01)

Low-dose rituximab followed by mycophenolate mofetil for steroid-dependent/frequently relapsing nephrotic syndrome in children: a case series
by: Jide Song, et al.
Published: (2025-08-01)

NEPHROTIC EDEMATA: WHY THERAPY IS NOT ALWAYS EFFECTIVE?
by: A. M. Rivkin
Published: (2013-11-01)

Is There a Diagnostic and Prognostic Role for Anti-Nephrin Autoantibodies in Diabetic Nephropathy?
by: Han Sean Lee, et al.
Published: (2025-03-01)

Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review
by: Xiao-yu Jing, et al.
Published: (2025-08-01)

Advancing the Treatment of Adult Steroid-Resistant Nephrotic Syndrome: The Role of Rituximab
by: Dmytro Ivanov, et al.
Published: (2025-03-01)

Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study
by: Xiaoyan Ma, et al.
Published: (2023-12-01)

Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up
by: Dmytro Ivanov, et al.
Published: (2024-11-01)

The efficacy and safety of rituximab in the maintenance treatment of first-episode minimal change nephrotic syndrome
by: Wang Ling, et al.
Published: (2025-05-01)